Concinnity
The company’s RNA-based systems enable the precise control of gene therapies even after dosing, meaning they can respond to and reduce their own side effects.
Edinburgh, UKwww.concinnitygenetics.com ↗
Total raised
€3.6M
€3,616,929
Funding rounds
1
Investors
4
distinct backers
Active since
2024-12
latest 2024-12
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood48
base rate 44% for Seed
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-12-16 | Seed | €3.6M | Eos Advisory,Maven Capital Partners,Old College Capital (OCC) - the University of Edinburgh’s in-house venture investment fund,Scottish Enterprise | View deal → |